IACH Journal Club-Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 Current Status Not Enrolled Price Free Get Started Log In to Enroll Course Content Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): phase 2 trial Final Quiz
